ArticleJournal of breast cancer2018
Microinvasive Carcinoma versus Ductal Carcinoma
Article in Journal of breast cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Meta-analysis on axillary lymph node metastasis rate in ductal carcinoma in situ with microinvasion.Cancer medicine · 2024Pooled it
- Prognostic significance of microinvasion with ductal carcinoma in situ of the breast: a meta-analysis.Breast cancer research and treatment · 2023Pooled it
- Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population-based analysis.Cancer medicine · 2022Trial
- Refining Sentinel Lymph Node Biopsy Decisions for Clinically Node-Negative Microinvasive DCIS.The breast journal · 2026Article
- DCIS Progression and the Tumor Microenvironment: Molecular Insights and Prognostic Challenges.Cancers · 2025Review
- Is the risk of local recurrence higher for microinvasive breast cancer vs. early stage invasive breast cancer?Breast cancer research and treatment · 2025Article
- Treatment patterns and clinical outcomes of patients with HER2-positive T1micN0 breast cancer: a single-center analysis.NPJ breast cancer · 2025Article
- Adherence to guideline recommendations for follow-up in patients with DCIS at a large teaching hospital in the Netherlands.Breast cancer research and treatment · 2024Article
- Unveiling the Clinical Path of Microinvasive Breast Cancer: A Comparative Study With Tis-T1 Breast Cancer.Cancer medicine · 2024Article
- Impact of surgical types on overall survival in patients with ductal carcinomaGland surgery · 2024Article
- A clinical radiomics nomogram preoperatively to predict ductal carcinoma in situ with microinvasion in women with biopsy-confirmed ductal carcinoma in situ: a preliminary study.BMC medical imaging · 2023Article
- Clinical significance of microinvasive breast cancer across the different subtypes and human epidermal growth factor receptor 2 expression levels.Breast cancer research and treatment · 2023Article
- Prognostic Markers of Microinvasive Breast Carcinoma: A Systematic Review and Meta-Analysis.Cancers · 2023Review
- Ductal Carcinoma In Situ (DCIS) and Microinvasive DCIS: Role of Surgery in Early Diagnosis of Breast Cancer.Healthcare (Basel, Switzerland) · 2023Review
- Clinicopathological characteristics, treatments, and prognosis of breast ductal carcinoma in situ with microinvasion: A narrative review.Chronic diseases and translational medicine · 2023Review
- Ductal carcinoma in situ with and without microinvasion: is there a clinically meaningful difference in outcome?British journal of cancer · 2023Article
- Application of deep learning to identify ductal carcinomaQuantitative imaging in medicine and surgery · 2022Article
- Microinvasive breast cancer and the role of sentinel lymph node biopsy.Scientific reports · 2022Article
- Regional Lymph Node Metastasis and Axillary Surgery of Microinvasive Breast Cancer: A Population-Based Study.Diagnostics (Basel, Switzerland) · 2022Article
- The Role of Trastuzumab in Patients with HER2 Positive Small (pT1mi/a) Breast Cancers, a Multicenter Retrospective Study.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough microinvasive carcinoma is distinct from ductal carcinoma
methodsWe assessed 613 cases of DCIS and microinvasive carcinoma that were consecutively resected from 2003 to 2014 and analyzed clinicopathological variables, expression of standard biomarkers such as the estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), p53, and Ki-67, and tumor recurrence.
resultsAmong the 613 cases, 136 (22.2%) were classified as microinvasive carcinoma. Microinvasive carcinoma was significantly associated with DCIS with a large extent, high nuclear grade, necrosis, and comedotype architectural pattern. ER and PR expressions were dominantly observed in pure DCIS, whereas positive HER2 status, p53 overexpression, and high Ki-67 proliferation indices were more frequently observed in microinvasive carcinoma. Lymph node metastasis was found in only four cases of microinvasive carcinoma with multifocal microinvasion. In the multivariate analysis, DCIS with a large extent, comedo-type architectural pattern, and negative ER status were found to be independent predictors of microinvasion. During follow-up, 12 patients had ipsilateral breast recurrence, and no differences in recurrence rates were observed between patients with DCIS and those with microinvasive carcinoma. The triple-negative subtype was the only factor that was associated with tumor recurrence.
conclusionMicroinvasive carcinomas are distinct from DCIS in terms of clinicopathological features and biomarker expressions but are similar to DCIS in terms of clinical outcomes. Our results suggest that microinvasive carcinoma can be treated and followed up as pure DCIS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.